Payer Perspectives

In this AJMC Payer Perspectives series, expert panelists discuss key updates and clinical insights related to ATTR-CM. The discussion focuses on the clinical and economic burden of the disease, diagnostic challenges and their impact on patient outcomes and costs, the mechanisms and pivotal trial data behind available disease-modifying therapies, practical therapy selection considerations, and how payers can implement value-based frameworks, utilization management strategies, and real-world evidence generation to support sustainable, evidence-driven coverage decisions.

Panelists discuss the clinical and economic burden of lupus nephritis, strategies for optimizing its management through early diagnosis and updated guidelines, and the importance of multidisciplinary care and collaboration between health care providers and payers to improve patient outcomes and access to treatment.

Ryan Haumschild, PharmD, MBA, leads a discussion with Heidi Crayton, MD, and Maria Lopes, MD, on the current treatment landscape for multiple sclerosis, novel therapies, step therapy, and guidelines for disease management.

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, explore the advancement of topical treatments and treatment sequencing for atopic dermatitis (AD), while also providing valuable insights from the payer's perspective.

Experts discuss financial considerations driving RSV treatment in pediatric patients.

Expert panelists provide payer considerations pertaining to the treatment of MDD.